No­vo surges on up­beat Q4 re­view and a move to pro­duce We­govy in-house. But charge of in­sulin price ma­nip­u­la­tion lingers

No­vo Nordisk shares $NO­VO surged close to 3% on Wednes­day morn­ing as ris­ing prof­its, a key beat on the num­bers and ev­i­dence that the phar­ma gi­ant is putting its man­u­fac­tur­ing woes in the rearview mir­ror en­cour­aged a shaky set of in­vestors to buy in­to a low-risk per­former in the big cap are­na.

No­vo got hit when its man­u­fac­tur­er for We­govy — their weight-loss ver­sion of the block­buster di­a­betes drug semaglu­tide — had to shut­ter pro­duc­tion af­ter they were hand­ed a 483 by FDA reg­u­la­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER